{"id":1420,"date":"2024-10-18T19:59:05","date_gmt":"2024-10-18T17:59:05","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/"},"modified":"2024-10-18T19:59:07","modified_gmt":"2024-10-18T17:59:07","slug":"la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/","title":{"rendered":"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d&rsquo;arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2024\/methadone-tied-to-lowe.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2024\/methadone-tied-to-lowe.jpg\" data-sub-html=\"\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>Selon une \u00e9tude publi\u00e9e en ligne le 17 octobre dans <i>JAMA<\/i>.<\/p>\n<p>Bohdan Nosyk, Ph.D., de l&rsquo;Universit\u00e9 Simon Fraser \u00e0 Burnaby, Colombie-Britannique, Canada, et ses coll\u00e8gues ont \u00e9valu\u00e9 le risque d&rsquo;arr\u00eat du traitement et de mortalit\u00e9 chez les personnes recevant de la bupr\u00e9norphine\/naloxone par rapport \u00e0 la m\u00e9thadone pour le traitement des troubles li\u00e9s \u00e0 l&rsquo;usage d&rsquo;opio\u00efdes. L\u2019analyse a port\u00e9 sur 30\u00a0891 utilisateurs adultes incidents (2010 \u00e0 2020) qui n\u2019\u00e9taient pas incarc\u00e9r\u00e9s, enceintes ou recevant des soins palliatifs contre le cancer.<\/p>\n<p>Les chercheurs ont constat\u00e9 que les utilisateurs occasionnels de bupr\u00e9norphine\/naloxone pr\u00e9sentaient un risque plus \u00e9lev\u00e9 d&rsquo;arr\u00eat du traitement que la m\u00e9thadone dans les analyses des initiateurs (88,8 contre 81,5 % d&rsquo;arr\u00eats \u00e0 24 mois\u00a0; rapport de risque (HR) ajust\u00e9 de 1,58). Des r\u00e9sultats similaires ont \u00e9t\u00e9 obtenus lors d&rsquo;une \u00e9valuation \u00e0 la dose optimale dans une analyse per protocole (42,1 contre 30,7\u00a0%\u00a0; HR ajust\u00e9, 1,67).<\/p>\n<p>La mortalit\u00e9 pendant le traitement a montr\u00e9 des r\u00e9sultats ambigus dans les analyses per protocole (utilisateurs incidents\u00a0: 0,08 contre 0,13\u00a0% de mortalit\u00e9 \u00e0 24\u00a0mois\u00a0; HR ajust\u00e9, 0,57\u00a0; intervalle de confiance (IC) \u00e0 95\u00a0%, 0,24 \u00e0 1,35\u00a0; utilisateurs pr\u00e9valents\u00a0: 0,08 contre 0,09\u00a0%\u00a0; HR ajust\u00e9, 0,97\u00a0; IC \u00e0 95\u00a0%, 0,54 \u00e0 1,73). Des r\u00e9sultats similaires ont \u00e9t\u00e9 observ\u00e9s apr\u00e8s l\u2019introduction du fentanyl et dans tous les sous-groupes de patients.<\/p>\n<p>\u00ab\u00a0Alors que l&rsquo;utilisation d&rsquo;opio\u00efdes synth\u00e9tiques plus puissants continue d&rsquo;augmenter en Am\u00e9rique du Nord et ailleurs, les lignes directrices cliniques pour tous les aspects du traitement des personnes souffrant de troubles li\u00e9s \u00e0 l&rsquo;usage d&rsquo;opio\u00efdes doivent \u00eatre reconsid\u00e9r\u00e9es afin de r\u00e9duire le risque d&rsquo;arr\u00eat du traitement\u00a0\u00bb, \u00e9crivent les auteurs.<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Selon une \u00e9tude publi\u00e9e en ligne le 17 octobre dans JAMA. Bohdan Nosyk, Ph.D., de<\/p>\n","protected":false},"author":1,"featured_media":1421,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[76,1792,1791,223,425,1110,540,257,40,261],"class_list":["post-1420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-addictions","tag-associee","tag-buprenorphinenaloxone","tag-darret","tag-est","tag-faible","tag-methadone","tag-par","tag-rapport","tag-risque","tag-traitement","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d&#039;arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d&#039;arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"Selon une \u00e9tude publi\u00e9e en ligne le 17 octobre dans JAMA. Bohdan Nosyk, Ph.D., de\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-18T17:59:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-18T17:59:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d&rsquo;arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone\",\"datePublished\":\"2024-10-18T17:59:05+00:00\",\"dateModified\":\"2024-10-18T17:59:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/\"},\"wordCount\":293,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg\",\"keywords\":[\"associ\u00e9e\",\"bupr\u00e9norphinenaloxone\",\"darr\u00eat\",\"est\",\"faible\",\"m\u00e9thadone\",\"par\",\"rapport\",\"risque\",\"traitement\"],\"articleSection\":[\"Les addictions\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/\",\"name\":\"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d'arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg\",\"datePublished\":\"2024-10-18T17:59:05+00:00\",\"dateModified\":\"2024-10-18T17:59:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg\",\"width\":1280,\"height\":853,\"caption\":\"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d'arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d&rsquo;arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d'arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/","og_locale":"fr_FR","og_type":"article","og_title":"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d'arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone - RVH-Synergie.org","og_description":"Selon une \u00e9tude publi\u00e9e en ligne le 17 octobre dans JAMA. Bohdan Nosyk, Ph.D., de","og_url":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/","og_site_name":"RVH-Synergie","article_published_time":"2024-10-18T17:59:05+00:00","article_modified_time":"2024-10-18T17:59:07+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d&rsquo;arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone","datePublished":"2024-10-18T17:59:05+00:00","dateModified":"2024-10-18T17:59:07+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/"},"wordCount":293,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg","keywords":["associ\u00e9e","bupr\u00e9norphinenaloxone","darr\u00eat","est","faible","m\u00e9thadone","par","rapport","risque","traitement"],"articleSection":["Les addictions"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/","url":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/","name":"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d'arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg","datePublished":"2024-10-18T17:59:05+00:00","dateModified":"2024-10-18T17:59:07+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/10\/1729274345_La-methadone-est-associee-a-un-risque-plus-faible-darret.jpg","width":1280,"height":853,"caption":"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d'arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/la-methadone-est-associee-a-un-risque-plus-faible-darret-du-traitement-par-rapport-a-la-buprenorphine-naloxone\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"La m\u00e9thadone est associ\u00e9e \u00e0 un risque plus faible d&rsquo;arr\u00eat du traitement par rapport \u00e0 la bupr\u00e9norphine\/naloxone"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/1420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=1420"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/1420\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/1421"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=1420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=1420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=1420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}